Posts Tagged ‘obesity’

ECO2025 in Málaga, Spain, today (Sunday) started off with a sweeping review of weight bias, obesity stigma, and strategies for ending them. It’s a big ambition. But it was an honor for ConscienHealth to participate with an array of experts in the subject. The thought to take away from it is simply that progress is […]

As we are on the way to the European Congress on Obesity in  Málaga, Spain, one thing stands out. The science presented at this conference will make it plain that obesity is about much more than just excess weight and weight loss.We are looking forward to an array of presentations that deal with the effects […]

A new study in JAMA Surgery adds to the impression that long-term outcomes are better with gastric bypass surgery when compared to gastric sleeve procedures for treating obesity. Specifically researchers found that people who have gastric bypass surgery are better than one third less likely to have heart attacks than those who have a gastric […]

David Kessler is the former FDA Commissioner who laid the groundwork for aggressive tobacco regulation with a simple metaphor. He argued that nicotine is addictive like heroin or cocaine. Now he and many others are working to stretch that metaphor to warn the public about addictive junk food. It is a simple and very appealing […]

Rather quietly this week, Eli Lilly and Company announced that it had withdrawn an application to FDA for an indication to use tirzepatide (Zepbound) in treating heart failure – specifically for HFpEF. This news came up in a briefing for investors, with Lilly’s Chief Scientific Officer, Dan Skovronsky, saying: “Following discussions with the FDA, we’ve […]

Late yesterday, the New England Journal of Medicine published interim results from a study that points to another breakthrough for semaglutide – this time for a MASH indication. The analysis includes 800 patients with MASH with an average BMI of 34.5. Only 22 patients in this trial had a BMI that indicated leanness. Nearly two […]

Mass market compounding of semaglutide and tirzepatide is pretty much a thing of the past. As that chapter in the story of inadequate access to care closes, it seems that Novo Nordisk is ready to go all in with telehealth deals to make up some lost ground. Their press release spells it out: “Today, Novo […]

Happy headlines late last year told us that obesity recently “dipped” in the U.S., perhaps because of medicines like semaglutide and tirzepatide. Those headlines presented a partial and misleading truth that a new analysis in Lancet Diabetes & Endocrinology explains more fully. Yes, the prevalence of overweight and mild obesity has seemingly plateaued. But this […]

Our Secretary of Health and Human Services, Robert F. Kennedy Jr., has a knack for raising ire. He does it in many ways. But on the diverse subjects of autism and obesity he uses the same word – preventable – to do it. The problem is not the word itself. The problem comes from false […]

An enduring and versatile mainstay of therapy for type 2 diabetes, metformin never ceases to earn our respect. On Thursday in JAMA, researchers showed this humble drug delivers improvements in knee pain for persons with overweight or obesity and osteoarthritis. In this six-month study of 107 persons randomized to either placebo or up to 2,000 […]